Postprandial increase in glucagon-like peptide-1 is blunted in severe heart failure
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society..
The relationship between disturbances in glucose homeostasis and heart failure (HF) progression is bidirectional. However, the mechanisms by which HF intrinsically impairs glucose homeostasis remain unknown. The present study tested the hypothesis that the bioavailability of intact glucagon-like peptide-1 (GLP-1) is affected in HF, possibly contributing to disturbed glucose homeostasis. Serum concentrations of total and intact GLP-1 and insulin were measured after an overnight fast and 15 min after the ingestion of a mixed breakfast meal in 49 non-diabetic patients with severe HF and 40 healthy control subjects. Similarly, fasting and postprandial serum concentrations of these hormones were determined in sham-operated rats, and rats with HF treated with an inhibitor of the GLP-1-degrading enzyme dipeptidyl peptidase-4 (DPP4), vildagliptin, or vehicle for 4 weeks. We found that HF patients displayed a much lower increase in postprandial intact and total GLP-1 levels than controls. The increase in postprandial intact GLP-1 in HF patients correlated negatively with serum brain natriuretic peptide levels and DPP4 activity and positively with the glomerular filtration rate. Likewise, the postprandial increases in both intact and total GLP-1 were blunted in HF rats and were restored by DPP4 inhibition. Additionally, vehicle-treated HF rats displayed glucose intolerance and hyperinsulinemia, whereas normal glucose homeostasis was observed in vildagliptin-treated HF rats. We conclude that the postprandial increase in GLP-1 is blunted in non-diabetic HF. Impaired GLP-1 bioavailability after meal intake correlates with poor prognostic factors and may contribute to the establishment of a vicious cycle between glucose disturbance and HF development and progression.
Errataetall: |
CommentIn: Clin Sci (Lond). 2020 Dec 11;134(23):3119-3121. - PMID 33269792 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:134 |
---|---|
Enthalten in: |
Clinical science (London, England : 1979) - 134(2020), 9 vom: 15. Mai, Seite 1081-1094 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Arruda-Junior, Daniel F [VerfasserIn] |
---|
Links: |
---|
Themen: |
89750-14-1 |
---|
Anmerkungen: |
Date Completed 07.10.2020 Date Revised 17.03.2021 published: Print CommentIn: Clin Sci (Lond). 2020 Dec 11;134(23):3119-3121. - PMID 33269792 Citation Status MEDLINE |
---|
doi: |
10.1042/CS20190946 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM309362652 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM309362652 | ||
003 | DE-627 | ||
005 | 20231225133739.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1042/CS20190946 |2 doi | |
028 | 5 | 2 | |a pubmed24n1031.xml |
035 | |a (DE-627)NLM309362652 | ||
035 | |a (NLM)32352510 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Arruda-Junior, Daniel F |e verfasserin |4 aut | |
245 | 1 | 0 | |a Postprandial increase in glucagon-like peptide-1 is blunted in severe heart failure |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 07.10.2020 | ||
500 | |a Date Revised 17.03.2021 | ||
500 | |a published: Print | ||
500 | |a CommentIn: Clin Sci (Lond). 2020 Dec 11;134(23):3119-3121. - PMID 33269792 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society. | ||
520 | |a The relationship between disturbances in glucose homeostasis and heart failure (HF) progression is bidirectional. However, the mechanisms by which HF intrinsically impairs glucose homeostasis remain unknown. The present study tested the hypothesis that the bioavailability of intact glucagon-like peptide-1 (GLP-1) is affected in HF, possibly contributing to disturbed glucose homeostasis. Serum concentrations of total and intact GLP-1 and insulin were measured after an overnight fast and 15 min after the ingestion of a mixed breakfast meal in 49 non-diabetic patients with severe HF and 40 healthy control subjects. Similarly, fasting and postprandial serum concentrations of these hormones were determined in sham-operated rats, and rats with HF treated with an inhibitor of the GLP-1-degrading enzyme dipeptidyl peptidase-4 (DPP4), vildagliptin, or vehicle for 4 weeks. We found that HF patients displayed a much lower increase in postprandial intact and total GLP-1 levels than controls. The increase in postprandial intact GLP-1 in HF patients correlated negatively with serum brain natriuretic peptide levels and DPP4 activity and positively with the glomerular filtration rate. Likewise, the postprandial increases in both intact and total GLP-1 were blunted in HF rats and were restored by DPP4 inhibition. Additionally, vehicle-treated HF rats displayed glucose intolerance and hyperinsulinemia, whereas normal glucose homeostasis was observed in vildagliptin-treated HF rats. We conclude that the postprandial increase in GLP-1 is blunted in non-diabetic HF. Impaired GLP-1 bioavailability after meal intake correlates with poor prognostic factors and may contribute to the establishment of a vicious cycle between glucose disturbance and HF development and progression | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a glucagon-like peptide-1 | |
650 | 4 | |a glucose homeostasis | |
650 | 4 | |a heart failure | |
650 | 7 | |a Blood Glucose |2 NLM | |
650 | 7 | |a C-Peptide |2 NLM | |
650 | 7 | |a Insulin |2 NLM | |
650 | 7 | |a Peptide Fragments |2 NLM | |
650 | 7 | |a Glucagon-Like Peptide 1 |2 NLM | |
650 | 7 | |a 89750-14-1 |2 NLM | |
700 | 1 | |a Martins, Flavia L |e verfasserin |4 aut | |
700 | 1 | |a Salles, Thiago Almeida |e verfasserin |4 aut | |
700 | 1 | |a Jensen, Leonardo |e verfasserin |4 aut | |
700 | 1 | |a Dariolli, Rafael |e verfasserin |4 aut | |
700 | 1 | |a Antonio, Ednei L |e verfasserin |4 aut | |
700 | 1 | |a Dos Santos, Leonardo |e verfasserin |4 aut | |
700 | 1 | |a Crajoinas, Renato O |e verfasserin |4 aut | |
700 | 1 | |a Tucci, Paulo J F |e verfasserin |4 aut | |
700 | 1 | |a Gowdak, Luís Henrique W |e verfasserin |4 aut | |
700 | 1 | |a Krieger, José Eduardo |e verfasserin |4 aut | |
700 | 1 | |a Pereira, Alexandre C |e verfasserin |4 aut | |
700 | 1 | |a Girardi, Adriana C |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical science (London, England : 1979) |d 1980 |g 134(2020), 9 vom: 15. Mai, Seite 1081-1094 |w (DE-627)NLM000401536 |x 1470-8736 |7 nnns |
773 | 1 | 8 | |g volume:134 |g year:2020 |g number:9 |g day:15 |g month:05 |g pages:1081-1094 |
856 | 4 | 0 | |u http://dx.doi.org/10.1042/CS20190946 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 134 |j 2020 |e 9 |b 15 |c 05 |h 1081-1094 |